

MINIREVIEW

Ligand- and Heterodimer-Directed Signaling of the CB₁ Cannabinoid Receptor

Brian D. Hudson, Terence E. Hébert, and Melanie E. M. Kelly

Departments of Pharmacology (B.D.H., M.E.M.K.) and Ophthalmology (M.E.M.K.), Dalhousie University, Halifax, Nova Scotia, Canada; and the Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (T.E.H.)

Received August 11, 2009; accepted October 15, 2009

ABSTRACT

Seven-transmembrane G protein-coupled receptors (GPCRs) represent the single largest family of cell surface receptors. Signaling through these receptors is controlled by changes in the conformation of the receptor from inactive to active conformations, which in turn lead to the activation of multiple downstream signaling pathways. To facilitate greater diversity in signaling responses, many of these receptors are capable of adopting several distinct active conformations, in which each couples preferentially to its own set of downstream signaling partners. Because these unique signaling

responses result from specific receptor active conformations, GPCR signaling may be directed toward these selective responses through either strength-of-signal effects resulting from partial agonism or through biased agonism and functional selectivity, resulting from the selective stabilization of one active conformation over the others. This review uses the CB₁ cannabinoid receptor as a specific example to highlight the contribution of two important aspects of GPCR function—orthosteric ligand binding and receptor heterodimerization—toward directed GPCR signaling.

Seven-transmembrane G protein-coupled receptors (GPCRs) are the single largest family of receptors localized to the cell surface and represent the most common target for currently available therapeutics (Jacoby et al., 2006). These receptors are typically defined by both their seven-membrane-spanning regions and their ability to couple with, and signal through, heterotrimeric guanine nucleotide binding proteins (G proteins). By tradition, GPCRs were believed to exist as monomers at the cell membrane, in which agonist binding would lead to the recruitment of a specific GDP-bound G protein, followed by the exchange of GTP for GDP, subsequently allowing the activated G protein to then act on its downstream effectors and produce a biological response (Gether, 2000). However, as our understanding of GPCR function has evolved, it has become apparent that such a model is far too simple to fully explain the complex pharmacology of these important signal transduction proteins.

Like other proteins, GPCRs may adopt many different structural conformations. Most importantly, these receptors switch between active conformations, capable of activating G proteins, and an inactive conformation that does not activate G proteins (Kenakin, 2001). Signaling through the GPCR is, therefore, determined by the relative stability of the active conformation compared with the inactive conformation of the receptor. In the absence of ligand, receptors typically adopt the inactive state. However, many GPCRs show an appreciable proportion of the active state, even in the absence of ligand, resulting in ligand-independent constitutive activity (Costa and Herz, 1989; Chidiac et al., 1994; Bond and Ijzerman, 2006). In this model of GPCR activation, agonist binding simply stabilizes the active conformation of the receptor and, thus, facilitates an increase in the proportion of receptors in the active state compared with those in the inactive state. An inverse agonist is thus defined as a ligand that stabilizes the inactive conformation of the receptor, reducing constitutive receptor signaling, whereas a neutral antagonist binds with no preference for the active or inactive conforma-

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.
doi:10.1124/mol.109.060251.

ABBREVIATIONS: GPCR, G protein-coupled receptor; 2-AG, 2-arachidonylglycerol; AEA, *N*-arachidonylethanolamine or anandamide; β_2 AR, β_2 adrenergic receptor; CNS, central nervous system; G protein, guanine nucleotide binding protein; MAEA, (*R*)-methanandamide; THC, (–)-*trans*- Δ^9 -tetrahydrocannabinol; WIN, WIN 55,212-2; ERK, extracellular signal-regulated kinase; ICI 118,551, (±)-1-[2,3-(dihydro-7-methyl-1*H*-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol.

tions of the receptor, effectively trapping it at whatever level of activity existed in the absence of ligand (Kenakin, 2001).

Adding to the complexity of GPCR signaling, it is now clear that GPCRs are capable of adopting more than one active conformation, in which each active state is capable of stimulating an overlapping yet distinct group of downstream effectors (Berg et al., 1998; Kenakin, 2001). This may allow signaling through the receptor to be directed through one pathway over the others through either strength-of-signal or biased agonism effects (Kenakin, 1995a,b). Strength-of-signal effects occur when a receptor is more strongly coupled to one of its signaling pathways than the others, and as a result, partial agonists not capable of fully activating the receptor may still completely activate the more strongly coupled signaling response while only partially activating the weakly coupled response (Fig. 1, A and B). The result of this is an agonist that will produce preferential signaling through pathways more strongly coupled to the receptor. In contrast, biased agonism occurs when agonist binding preferentially stabilizes one active signaling state over another (Fig. 1C) (Kenakin, 1995b; Berg et al., 1998). Similar to the strength-of-signal effects, this also results in preferential activation of one signaling pathway over another; however, unlike the strength-of-signal effects, biased agonism may selectively ac-

tivate any signaling pathways downstream of a given receptor, not only the most strongly coupled one. In recent years, the term “biased agonism” has become synonymous with additional terms to indicate selective activation of GPCR signaling pathways, including stimulus trafficking and, the one that has become most common, functional selectivity (Kenakin, 2001; Bosier et al., 2008a).

Directed signaling and functional selectivity is most easily detected in GPCRs that pleiotropically couple to more than one $G\alpha$ subtype (G_s , $G_{i/o}$, $G_{q/11}$, etc.), different active conformations of the receptor having differing abilities to couple with, and activate, each $G\alpha$ subtype (Bosier and Hermans, 2007). However, functionally selective active conformations may also influence G protein-independent signaling pathways (Drake et al., 2008) or even alter patterns of desensitization and internalization of activated receptors. This is the case for the μ -opioid receptor, in which some active conformations lead to receptor desensitization and internalization, whereas others do not (Keith et al., 1996; Blake et al., 1997).

Given that these different GPCR active states are the result of distinct conformations of the receptor, any interacting molecule with the ability to stabilize one particular active conformation over the others may also direct receptor signaling through that specific active state and, in turn, toward its




Fig. 1. Model of GPCR conformations and the resulting concentration-response curves for ligand- and heterodimer-directed signaling of a model GPCR. A, a model GPCR activated by a full agonist, ligand A, favors the G_i -coupled active state (blue) over the G_s -coupled active state (green). The resulting concentration-response shows a G_i response of greater efficacy than that of the G_s response. B, ligand B directs signaling toward G_i via strength-of-signal effects. Ligand B is a partial agonist with less efficacy than ligand A for the model receptor. As a result, ligand B activates the poorly coupled G_s pathway to a lesser extent than does ligand A, yet ligand B is still fully capable of activating the strongly coupled G_i pathway of the receptor. Instead, if ligands A and B have similar affinities for the receptor, the reduced efficacy of ligand B compared with A will result in the reduced potency of B to activate the strongly coupled G_i pathway and, in turn, a rightward shift in the concentration-response curve. C, biased agonism or true functional selectivity of the model GPCR is produced by the binding of ligand C. In this case, the ligand preferentially stabilizes the G_s -coupled active state of the receptor over the G_i -coupled state, resulting in increased G_s signaling efficacy compared with ligand A but decreased G_i signaling efficacy. D, heterodimer-directed signaling of the model GPCR favoring G_s signaling. When the model GPCR heterodimerizes with another GPCR (brown receptor), the G_s -coupled state is stabilized over the G_i -coupled state through allosteric effects. As a result, when acting on the heterodimer, ligand A no longer activates the G_i pathway but still activates the G_s pathway.

unique set of signaling pathways. In a model of GPCR activation that includes multiple active receptor conformations, different orthosteric agonist ligands may selectively bind to and stabilize specific active conformations of the receptor, resulting in ligand-directed functional selectivity (Kenakin, 1995b). In some cases, such directed selectivity can be so extreme that a ligand that acts as an inverse agonist in one pathway can be an agonist for another. For example, the β_2 -adrenergic receptor (β_2 AR) ligand ICI 118,551 is an inverse agonist for the β_2 AR/ G_s -coupled cAMP response while concurrently acting as an agonist to a β_2 AR/ G protein-independent, β -arrestin-mediated ERK mitogen-activated protein kinase signaling pathway (Azzi et al., 2003; Baker et al., 2003).

In addition to orthosteric ligand binding, allosteric effects on GPCRs may also affect receptor conformation and generate functional selectivity, either through ligand binding to allosteric sites, or through protein-protein interactions with the receptor (Bosier and Hermans, 2007; Leach et al., 2007; Piñeyro, 2009). Although allosteric ligands have been shown to produce functional selectivity in GPCR signaling for a few receptors (Maillet et al., 2007; Valant et al., 2008), the majority of work in this area has focused on how the protein-protein interactions of GPCRs may result in functional selectivity. Given that many of the downstream effectors activated by GPCRs, including adenylyl cyclase and K^+ and Ca^{2+} channels, form stable complexes with the receptor at the cell surface, it might be expected that direct receptor-effector physical interactions are capable of producing functionally selective signaling responses (Piñeyro, 2009). Recent observations have also demonstrated that $G\alpha$ subunits may themselves alter the conformation of the receptor to affect ligand affinity and signaling (Yan et al., 2008).

In addition to the effects of G proteins and downstream effectors, when considering receptor-protein interactions, a significant amount of attention has been directed toward examining the influence of GPCR heterodimerization on the functional selectivity of these receptors. The first clear evidence that family A GPCRs form dimers or higher-order oligomers came with the demonstration of a β_2 AR homodimer (Hebert et al., 1996; Angers et al., 2000). Since then, it has been found that most GPCRs form homodimers and heterodimers with other GPCRs (Pfleger and Eidne, 2005; Dalrymple et al., 2008; Panetta and Greenwood, 2008) and that these interactions influence many aspects of receptor function (Terrillon and Bouvier, 2004). One important aspect of GPCR function that may be affected by GPCR heterodimerization is the G protein-coupling preference of the receptors present in the dimer (George et al., 2000; Charles et al., 2003; Breit et al., 2004; Terrillon and Bouvier, 2004). As a result, a ligand that does not show functional selectivity in the absence of heterodimerization may produce a functionally selective response of the heterodimer because the second interacting receptor of the dimer stabilizes one active conformation over the others (Fig. 1D). Heterodimerization of these receptors, therefore, can be viewed as another means to direct functional selectivity in downstream signaling pathways that each receptor in the complex activates. The possibility of developing bivalent orthosteric ligands for heterodimers or bivalent orthosteric/allosteric modulators for GPCR homo- and heterodimers significantly increases drug development possibilities (Waldhoer et al., 2005; Valant et al., 2009).

Whether such bitopic modulators might be designed to be functionally selective remains to be seen. This review compares ligand- and heterodimer-directed signaling of GPCRs, using the CB₁ cannabinoid receptor as a specific example.

The CB₁ Cannabinoid Receptor

First recognized for its ability to bind to and produce the psychotropic effects of the active agent of the plant *Cannabis sativa* (Matsuda et al., 1990), the CB₁ receptor has since become of significant physiological, pharmacological, and clinical interest. CB₁ is widely expressed both in the central nervous system (CNS) and in the periphery and is one of the central components of the endocannabinoid system composed of the cannabinoid receptors CB₁ and CB₂; the endocannabinoid ligands, including *N*-arachidonylethanolamine or anandamide (AEA) and 2-arachydonylglycerol (2-AG); and the metabolic enzymes responsible for the production and breakdown of these ligands (Rodríguez de Fonseca et al., 2005). The endocannabinoid system, in particular CB₁, has generated considerable research interest as a potential therapeutic target in the treatment of a plethora of conditions, including pain, metabolic syndrome, neurological and psychiatric disorders, and addiction, among others (Piomelli et al., 2000; Croxford, 2003; Vinod and Hungund, 2006; Hosking and Zajicek, 2008; Pertwee, 2008).

CB₁ provides a key example of both ligand- and heterodimer-directed GPCR functional selectivity. Stimulation of CB₁ leads primarily to the activation of $G_{i/o}$ proteins to inhibit adenylyl cyclase, activate mitogen-activated protein kinases, inhibit voltage-dependent Ca^{2+} channels, and activate inwardly rectifying K^+ channels (Demuth and Molleman, 2006). However, activation of CB₁ also results in signaling through G_s proteins to activate adenylyl cyclase (Glass and Felder, 1997; Maneuf and Brotchie, 1997), as well as signaling through $G_{q/11}$ proteins to increase intracellular Ca^{2+} concentration (Lauckner et al., 2005; McIntosh et al., 2007). In addition to the fact that CB₁ couples with all three major $G\alpha$ subtypes, ligands acting at this receptor are quite diverse in both their chemical structures and pharmacological effects (Pertwee, 2006), making CB₁ ideal for the study of ligand-directed functional selectivity. Finally, because CB₁ has been shown to form heterodimers with several other receptors, including the D₂ dopamine receptor, μ , κ , and δ opioid receptors, the orexin-1 receptor, the A_{2A} adenosine receptor, and the β_2 AR (Kearn et al., 2005; Mackie, 2005; Ellis et al., 2006; Rios et al., 2006; Carriba et al., 2007; Hudson and Kelly, 2008), CB₁ is also a good candidate for examining heterodimer-directed GPCR functional selectivity.

Ligand-Directed Signaling of CB₁

Ligands with affinity for the CB₁ receptor are both structurally and pharmacologically diverse (Fig. 2). CB₁ agonists can be broadly divided into four structurally distinct classes: 1) the classic¹ cannabinoids, including natural compounds from the plant *C. sativa* such as (–)-*trans*- Δ^9 -tetrahydrocannabinol (THC), and its related synthetic derivatives (e.g., the highly potent HU-210); 2) the nonclassic² cannabinoids, which are similar to the classic cannabinoids except that they


¹ Also known as “classical.”

² Also known as “nonclassical.”


lack the dihydropyran ring (e.g., CP 55,940); 3) the eicosanoids, which are derivatives of arachidonic acid and include the endocannabinoids AEA and 2-AG; and 4) the structurally distinct aminoalkylindoles, including WIN 55212-2 (WIN) and its related compounds (Howlett et al., 2002; Pertwee, 2006). The most common class of CB₁ antagonists is the diarylpyrazoles, compounds that are structurally dissimilar from the four classes of CB₁ agonists. These compounds are typically inverse agonists at CB₁ and are defined by the prototypical compound SR 141716 (Howlett et al., 2002). However, there are also examples of CB₁ antagonists with structures similar to those of the cannabinoid agonists. For example, the compound O-2050, which is a neutral antagonist at CB₁, is structurally similar to the classic cannabinoids (Gardner and Mallet, 2006).

Given the vast structural variation of the cannabinoid ligands, it is not surprising that they might possess significant selectivity in their ability to modulate the various CB₁ signaling pathways. This extends even to their actions on the classic pertussis toxin-sensitive G_{i/o} signaling pathway of CB₁. In a study directly comparing the levels G_i and G_o activation by various CB₁ ligands, only the classic cannabinoid HU-210 produced maximal activation of both G protein subtypes (Glass and Northup, 1999). The aminoalkylindole WIN and the endocannabinoid AEA produced maximal G_i responses but submaximal G_o responses, whereas THC produced submaximal responses for both G_i and G_o. These findings demonstrate clear ligand-directed signaling for WIN and AEA in favor of CB₁-G_i activation. Because CB₁ is more strongly coupled to G_i than it is to G_o (Glass and Northup,

(1) Classical Cannabinoids




THC




HU-210

(2) Non-classical Cannabinoids




CP55,940

(3) Eicosanoids




AEA
Anandamide

(4) Aminoalkylindoles




WIN55212-2

Diarylpyrazoles Inverse Agonists



SR141716

Classical Cannabinoid Antagonists



O-2050

Fig. 2. Chemical structures of representative cannabinoid ligands.

1999), this ligand-directed signaling may be due to either strength-of-signal or biased agonism effects of these ligands. Subsequent work examining the specific G_i subtypes activated by cannabinoid ligands has now shown that WIN activates all of the G_{i1}, G_{i2}, and G_{i3} subtypes as an agonist, whereas other ligands, including the classic cannabinoid desacetyl-levonantradol and the endocannabinoid (*R*)-methanandamide (MAEA), activate only some G_i isoforms as an agonist while acting as inverse agonists at others (Mukhopadhyay and Howlett, 2005). Such observations clearly indicate that within CB₁-G_i signaling, there is true functional selectivity in the activation of G_i subtypes, because these results cannot be explained by strength-of-signal ligand-directed effects. In this study, the CB₁ ligand SR141716 acted as an inverse agonist for all three subtypes of G_i. In addition, lending further support for the concept of true CB₁-G_i functional selectivity, a separate study comparing the nonclassic cannabinoid CP 55,940 with the aminoalkylindole WIN clearly demonstrated that each ligand stabilized a qualitatively different conformation of the CB₁ receptor, and these conformations had differing affinities for G_{i1} (Georgieva et al., 2008).

In addition to evidence directly showing G_{i/o} functional selectivity of CB₁ at the level of G protein activation, several reports have indirectly shown G_{i/o} ligand-directed selectivity in signaling pathways downstream of CB₁. The classic cannabinoid HU-210 and the nonclassic cannabinoid CP 55,940 have reciprocal effects on tyrosine hydroxylase expression, as well as having opposite effects on ERK versus c-Jun NH₂-terminal kinase phosphorylation in neuroblastoma N1E-115 cells, with HU-210 being more effective in activating ERK and CP 55,940 being more effective in activating c-Jun NH₂-terminal kinase (Bosier et al., 2007; Bosier et al., 2008b). Because these reciprocal responses to the two ligands were at least partially sensitive to pertussis toxin, it suggests that they are the result of CB₁-G_{i/o} subtype functional selectivity.

Under some circumstances, CB₁ may also signal through G_s to increase cAMP levels, in addition to its more traditional G_{i/o}-mediated pathway, extending the possibility of greater ligand-directed signaling and functional selectivity for this receptor (Maneuf and Brothie, 1997; Felder et al., 1998; Calandra et al., 1999). A careful examination of the effect of

various cannabinoid ligands on CB₁-G_s signaling showed clear ligand-directed signaling (Bonhaus et al., 1998). In particular, although WIN and HU-210 had comparable efficacies for the G_{i/o} and G_s signaling pathways, CP 55,940 and AEA both had a significant preference for the CB₁-G_i pathway. Further support for CP 55,940 being poorly linked to CB₁-G_s signaling came from the observation that a CB₁ mutant that constitutively activated G_s did not exhibit increased binding to this ligand (Abadji et al., 1999). The ligand SR141716, which is an inverse agonist for the classic G_{i/o} signaling pathway, seems to act as an inverse agonist for the G_s pathway as well, because in all cases, the CB₁-G_s response was blocked by SR141716, and this compound was also capable of attenuating the signaling of a CB₁ mutant constitutively active for G_s signaling (Maneuf and Brothie, 1997; Bonhaus et al., 1998; Abadji et al., 1999; Calandra et al., 1999). However, because the CB₁ receptor is not as strongly coupled to G_s as it is to G_i (Felder et al., 1998), these ligand-directed G_s responses may not be true biased agonism functional selectivity but instead may be the result of strength-of-signal effects resulting from HU-210 and WIN being stronger agonists than CP 55,940 and AEA.

The more recent observation that CB₁ also signals through G_{q/11} has added an additional level of complexity to the ligand-directed signaling of this receptor. In both a heterologous expression system using rat CB₁ and a human ocular cell line endogenously expressing CB₁, it was found that only the aminoalkylindole WIN was capable of activating CB₁-G_{q/11} signaling to increase intracellular Ca²⁺ levels, whereas all other CB₁ agonists tested, including HU-210, THC, CP55,940, and MAEA, did not facilitate CB₁-G_{q/11} signaling (Lauckner et al., 2005; McIntosh et al., 2007). The CB₁ inverse agonist SR141716 blocked the WIN response, indicating that it still acted as an antagonist, and possibly as an inverse agonist, for CB₁-G_{q/11} signaling.

Taken together, it is clear that complex ligand-directed signaling events can be detected for CB₁ (Table 1). This includes the true functional selectivity observed within CB₁-G_{i/o} and G_{q/11} signaling and CB₁-G_s-directed signaling, which may result from either ligand strength-of-signal effects or functional selectivity. Among the cannabinoid ligands, the aminoalkylindole WIN seems to be the least restrictive in its

TABLE 1
Summary of the ligand-directed signaling of CB₁

Ligand	G _i	G _o	G _s	G _{q/11}	References
Classic					
HU-210	++	++	++	N.E.	Bonhaus et al., 1998; Glass and Northup, 1999; Lauckner et al., 2005
THC	+	+	+	N.E.	
Nonclassic					
CP 55,940	++ ^a	×	+	N.E.	Bonhaus et al., 1998; Glass and Northup, 1999; Lauckner et al., 2005; McIntosh et al., 2007; Georgieva et al., 2008
Eicosanoid					
AEA	++ ^a	+	+	N.E. ^b	Bonhaus et al., 1998; Glass and Northup, 1999; Mukhopadhyay et al., 2005; McIntosh et al., 2007
Aminoalkylindole					
WIN	++	+	++	+	Bonhaus et al., 1998; Glass and Northup, 1999; Lauckner et al., 2005; Mukhopadhyay et al., 2005; McIntosh et al., 2007
Diarylpyrazole					
SR 141716	—	×	—	N.E. ^c	Abadji et al., 1999; Lauckner et al., 2005; Mukhopadhyay et al., 2005

+, agonist effect; —, inverse agonist effect; N.E., no agonist or inverse effect (compounds probably act as neutral antagonists); ×, has not been directly tested for G_o-specific coupling.

^a Acts as full G_i agonist but has reduced affinity or efficacy to specific G_i subtypes.

^b Data obtained with MAEA instead of AEA.

^c SR 141716 acted as an antagonist to the G_{q/11} pathway but was not tested as an inverse agonist.

ability to activate all of the various CB₁-G protein subtype pathways, acting as an agonist for each. In contrast, the diarylpyrazole ligands, including SR141716, act as inverse agonists or antagonists for every pathway. HU-210 also showed less selectivity than the other ligands, activating every pathway except G_{q/11}, whereas the nonclassic cannabinoid CP55,940 and the eicosanoids AEA and MAEA, possessed significantly greater selectivity in their abilities to activate all CB₁ signaling pathways examined.

Heterodimer-Directed CB₁ Signaling

Like many other GPCRs, CB₁ physically and functionally interacts with other GPCRs as dimers or higher-order oligomers. To date, CB₁ has been found to form homodimers as well as heterodimers with the D₂ dopamine receptor, the μ -, κ -, and δ -opioid receptors, the orexin-1 receptor, the A_{2A} adenosine receptor, and the β_2 AR (Wager-Miller et al., 2002; Kearn et al., 2005; Ellis et al., 2006; Rios et al., 2006; Carriba et al., 2007). These interactions have been demonstrated to influence several different aspects of CB₁ function, including the specific signaling pathways that are activated by cannabinoid agonists.

The most thoroughly studied CB₁ heterodimer with regard to its effect on CB₁ signaling is the CB₁/D₂ heterodimer. Even before a physical interaction between these two receptors had been demonstrated, it was observed that costimulation of CB₁ and D₂ in striatal neurons led to an accumulation of cAMP, whereas stimulation of either receptor alone led to an inhibition of cAMP (Glass and Felder, 1997). This response was suggested to be the result of CB₁ switching from G_i to G_s signaling if CB₁ was coactivated with the D₂ receptor. Thereafter, it was found that coexpression of the D₂ receptor alone was sufficient to switch CB₁ toward increased G_s coupling, even in the absence of a D₂ agonist (Jarrahian et al., 2004). Finally, with the demonstration that CB₁ does in fact form a heterodimer with D₂ by coimmunoprecipitation (Kearn et al., 2005), it can be suggested that the CB₁/D₂ interaction stabilizes a CB₁ active state with increased coupling to G_s. Because the initial study found that costimulation of the D₂ receptor was required for the CB₁ switch to G_s signaling (Glass and Felder, 1997), it is possible that it is only the active state of D₂ that facilitates this switch. If this is the case, CB₁-G_s switching in the absence of D₂ agonist can be explained by the fact that D₂ is a constitutively active receptor in some systems (Hall and Strange, 1997).

Similar to the effect of the CB₁/D₂ heterodimer on CB₁-G_s signaling, A_{2A} adenosine receptor coactivation was required for effective CB₁-G_i signaling, as measured by inhibition of forskolin-mediated cAMP accumulation, in the context of a CB₁/A_{2A} heterodimer (Carriba et al., 2007). When CB₁ and A_{2A} were coexpressed, CB₁ only signaled through G_i when A_{2A} was coactivated (Carriba et al., 2007), even though CB₁ effectively coupled to G_i when expressed alone (Felder et al., 1995). These findings indicate that the physical interaction between CB₁ and A_{2A} in the absence of an A_{2A} agonist results in a conformation of CB₁ that does not allow for CB₁-G_i signaling to occur. In contrast, the opposite effect seems to occur in the CB₁/ μ -opioid heterodimer. In this case, activation of either receptor alone within the heterodimer led to effective G_i signaling, but coactivation of both receptors resulted in inhibition of their G_i-mediated responses (Rios et al., 2006). Thus, it seems that only when the μ -opioid recep-

tor is in the active state is this receptor able to inhibit CB₁ signaling through G_i. It has not yet been determined for either the CB₁/A_{2A} and CB₁/ μ -opioid receptor heterodimers whether there is an effect on either CB₁-G_s- or CB₁-G_{q/11}-coupled signaling (Rios et al., 2006; Carriba et al., 2007), representing an important aspect of CB₁ pharmacology that deserves future attention.

Heterodimerization of CB₁ with β_2 AR also results in directed CB₁ signaling, which may be relevant to many of the tissues that coexpress these two receptors, including the brain, cardiovascular system, bone, eye, and reproductive tract (Jampel et al., 1987; Wanaka et al., 1989; Tsou et al., 1998; Stamer et al., 2001; Wang et al., 2004; Pacher and Haskó, 2008). Specifically, when CB₁ and β_2 AR are coexpressed, the G protein-coupling preference for CB₁ switches away from G_s and toward G_i (Hudson and Kelly, 2008). This was evident by an increase in CB₁-G_i-mediated pERK signaling and a decrease in CB₁-G_s-mediated phosphorylation of cAMP response element binding protein signaling when β_2 AR was present. Unlike the effects seen with the D₂ dopamine and A_{2A} adenosine receptors, this effect seems to be independent of the activation state of β_2 AR, because neither β_2 AR agonist nor antagonist significantly altered either CB₁ response.

In considering the overall influence of the various CB₁ heterodimers on CB₁-directed signaling and functional selectivity (Table 2), it is clear that heterodimer-directed signaling has the potential to be much more complex than ligand-directed signaling, because it depends not only on which GPCRs are present in the complex but also on the (possibly multiple) active states of each receptor. Further complicating the issue is the recent demonstration, using sequential resonance energy transfer, that CB₁ forms a hetero-oligomer with the D₂ receptor and the A_{2A} receptor (Carriba et al., 2008). This CB₁/D₂/A_{2A} complex probably results in even more complex CB₁ functional selectivity and directed signaling in cells that coexpress all three of these receptors.

Allosteric Ligands of CB₁ and Functional Selectivity

Despite the fact that allosteric ligands by definition alter receptor conformation through binding at sites distinct from the orthosteric ligand binding site, only recently has it been directly shown that these ligands produce functionally selec-

TABLE 2
Summary of heterodimer-directed CB₁ signaling

Heterodimer	G _{i/o}	G _s	References
CB ₁ Expressed alone	++	++	Felder et al., 1995; Hudson and Kelly, 2008
CB ₁ /D ₂ Activated D ₂	++	+++	Glass and Felder, 1997; Jarrahian et al., 2004; Kearn et al., 2005
Basal D ₂	++	++	
CB ₁ /A _{2A} Activated A _{2A}	++	N.D.	Carriba et al., 2007
Basal A _{2A}	—	N.D.	
CB ₁ / μ -opioid Activated μ -opioid	+	N.D.	Rios et al., 2006
Basal μ -opioid	++	N.D.	
CB ₁ / β_2 AR Active or basal β_2 AR	+++	+	Hudson and Kelly, 2008

+, CB₁ in heterodimer signals through this pathway; —, CB₁ in heterodimer does not signal through this pathway; N.D., not determined.

tive GPCR signaling responses (Leach et al., 2007; Maillet et al., 2007; Valant et al., 2008). CB₁ possesses at least one allosteric site, binding at which is typically associated with enhanced orthosteric agonist affinity yet decreased agonist efficacy (Price et al., 2005; Horswill et al., 2007; Ross, 2007). This contradictory effect suggests that allosteric ligands that bind at this site stabilize a CB₁ conformation with high agonist affinity but which is functionally less active (Ross, 2007). It is interesting that there does seem to be a ligand-specific component to the action of these allosteric modulators, because although they tend to enhance agonist binding, they inhibit the binding of the inverse agonist SR141716 (Price et al., 2005). This result may be explained if the receptor conformation stabilized by the allosteric ligand has a lower affinity for SR141716 but higher affinity for the CB₁ agonists. Although these results do not directly demonstrate CB₁ functional selectivity resulting from the binding of allosteric modulators, the fact that these modulators do seem to alter the conformation of CB₁ in such a way as to affect signaling efficacy suggests that such functionally selective CB₁ allosteric ligands may exist.

Conclusions

The ultimate goal in the development of any new therapeutic agent is to identify a drug that produces the desired effect with minimal side effects. To this end, the concept of directed signaling and functional selectivity has generated significant interest as a means to develop compounds that can selectively activate or block receptor-signaling pathways that lead only to the desired therapeutic effect. This is of particular importance for the CB₁ receptor as a potential druggable target for the treatment of pain, psychiatric, and neurodegenerative disorders given that many existing cannabinoid agonists for CB₁ are of little value therapeutically because of their unwanted psychotropic side effects (Croxford, 2003; Vinod and Hungund, 2006; Bambico and Gobbi, 2008; Bilsland and Greensmith, 2008; Hosking and Zajicek, 2008; Pazos et al., 2008; Pertwee, 2008). Several approaches have been undertaken to develop cannabinoid compounds that can produce analgesia with reduced psychotropic side effects. These include the development of CNS-excluded CB₁ ligands or targeting the nonpsychotropic CB₂ cannabinoid receptor (Agarwal et al., 2007; Hosking and Zajicek, 2008; Pertwee, 2008). However, because much of the therapeutic potential of cannabinoids lie in CNS-located CB₁ receptors (Croxford, 2003; Pertwee, 2008), neither of these strategies are likely to provide a complete solution. Instead, a combination of these approaches together with an approach that takes advantage of ligand- or heterodimer-directed CB₁ signaling may be the key to unlocking the full therapeutic potential of the cannabinoids.

Even with cannabinoid ligands already available, there is some promise to the idea of developing CB₁ agonists that produce only a desired therapeutic effect without the unwanted side effects. For example, it has been suggested that the reciprocal regulation of tyrosine hydroxylase, an enzyme involved in the synthesis of dopamine, by cannabinoid ligands HU-210 and CP 55,940 may present a means to develop cannabinoids with a reduced risk of addiction (Bosier and Hermans, 2007). This is still speculative, however, given that it is unclear which specific CB₁-signaling pathways should be activated to produce the desired therapeutic effects

versus which should be excluded to reduce the unwanted side effects. Only with the development of suitable functionally selective CB₁ ligands will these questions truly be answered in vivo. Unfortunately, there is still the possibility that even a fully selective ligand activating only one receptor pathway may not be able to separate desired from unwanted pharmacological effects if both effects are mediated by the same CB₁-signaling pathway through actions on different cells, regions, or tissues.

To resolve such problems, heterodimer-directed signaling may prove to be a useful solution. Heterodimer-directed signaling is more complex than the ligand-directed selectivity because it is influenced not only by the receptors present in the dimer but also by the active state of each receptor. However, it also presents a greater challenge for drug development because controlling which receptors heterodimerize in vivo will be difficult. Instead, the answer probably will be to generate ligands that selectively activate one specific GPCR heterodimer over others. Such heterodimer-selective ligands have long been proposed as a means to generate more functionally and regionally selective GPCR responses (Dalrymple et al., 2008; Panetta and Greenwood, 2008), because these ligands would only have actions in regions and tissues in which the targeted heterodimer is expressed. Recent work has begun to show promise in the development of such ligands for several GPCR heterodimer pairs, but it remains to be seen whether these ligands will be useful clinically (Daniels et al., 2005; Xie et al., 2005; Breit et al., 2006). The prospect of such ligands for CB₁, which are capable of activating specific CB₁ signaling pathways in specific cells and tissues, may be the final step in the development of psychotropically inactive, clinically useful CB₁ cannabinoid agonists.

Although much has been learned about the selectivity of CB₁ with respect to its pleiotropic coupling to various G protein subtypes, additional forms of CB₁ functional selectivity still need to be examined. For example, neither ligand-directed selectivity in receptor desensitization and internalization, as has been shown with the μ -opioid receptor (Keith et al., 1996; Blake et al., 1997), nor ligand-directed selectivity in G protein-independent signaling pathways, as has been demonstrated with β -arrestin-biased ligands for the β_2 AR (Drake et al., 2008), has been examined for CB₁. A more complete understanding of the ways in which these different forms of CB₁ functional selectivity are affected by cannabinoid ligands and heterodimer pairs is critical to the future development of effective therapeutics targeting the CB₁ receptor.

References

- Abadji V, Lucas-Lenard JM, Chin C, and Kendall DA (1999) Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB₁ receptor in constitutive activation of Gs. *J Neurochem* **72**:2032–2038.
- Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat Neurosci* **10**:870–879.
- Angers S, Salahpour A, Joly E, Hilairat S, Chelsky D, Dennis M, and Bouvier M (2000) Detection of β_2 -adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). *Proc Natl Acad Sci U S A* **97**:3684–3689.
- Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Piñeyro G (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. *Proc Natl Acad Sci U S A* **100**:11406–11411.
- Baker JG, Hall IP, and Hill SJ (2003) Agonist and inverse agonist actions of

- β -blockers at the human β_2 -adrenoceptor provide evidence for agonist-directed signaling. *Mol Pharmacol* **64**:1357–1369.
- Bambico FR and Gobbi G (2008) The cannabinoid CB₁ receptor and the endocannabinoid anandamide: possible antidepressant targets. *Expert Opin Ther Targets* **12**:1347–1366.
- Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. *Mol Pharmacol* **54**:94–104.
- Bilsland LG and Greensmith L (2008) The endocannabinoid system in amyotrophic lateral sclerosis. *Curr Pharm Des* **14**:2306–2316.
- Blake AD, Bot G, Freeman JC, and Reisine T (1997) Differential opioid agonist regulation of the mouse μ opioid receptor. *J Biol Chem* **272**:782–790.
- Bond RA and Ijzerman AP (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. *Trends Pharmacol Sci* **27**:92–96.
- Bonhaus DW, Chang LK, Kwan J, and Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. *J Pharmacol Exp Ther* **287**:884–888.
- Bosier B and Hermans E (2007) Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. *Trends Pharmacol Sci* **28**:438–446.
- Bosier B, Hermans E, and Lambert D (2008a) Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB₁ receptor. *Br J Pharmacol* **155**:24–33.
- Bosier B, Lambert DM, and Hermans E (2008b) Reciprocal influences of CB₁ cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells. *FEBS Lett* **582**:3861–3867.
- Bosier B, Tilleux S, Najimi M, Lambert DM, and Hermans E (2007) Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. *J Neurochem* **102**:1996–2007.
- Breit A, Gagnidze K, Devi LA, Lagacé M, and Bouvier M (2006) Simultaneous activation of the δ opioid receptor (δ OR)/sensory neuron-specific receptor-4 (SNSR-4) hetero-oligomer by the mixed bivalent agonist bovine adrenal medulla peptide 22 activates SNSR-4 but inhibits δ OR signaling. *Mol Pharmacol* **70**:686–696.
- Breit A, Lagacé M, and Bouvier M (2004) Hetero-oligomerization between β_2 - and β_3 -adrenergic receptors generates a β -adrenergic signaling unit with distinct functional properties. *J Biol Chem* **279**:28756–28765.
- Calandra B, Portier M, Kernéis A, Delpech M, Carillon C, Le Fur G, Ferrara P, and Shire D (1999) Dual intracellular signaling pathways mediated by the human cannabinoid CB₁ receptor. *Eur J Pharmacol* **374**:445–455.
- Carriba P, Navarro G, Ciruela F, Ferré S, Casadó V, Agnati L, Cortés A, Mallol J, Fuxe K, Canela EI, et al. (2008) Detection of heteromerization of more than two proteins by sequential BRET-FRET. *Nat Methods* **5**:727–733.
- Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F, et al. (2007) Striatal adenosine A_{2A} and cannabinoid CB₁ receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. *Neuropsychopharmacology* **32**:2249–2259.
- Charles AC, Mostovskaya N, Asas K, Evans CJ, Dankovich ML, and Hales TG (2003) Coexpression of δ -opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory. *Mol Pharmacol* **63**:89–95.
- Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of β -adrenergic antagonists. *Mol Pharmacol* **45**:490–499.
- Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. *Proc Natl Acad Sci U S A* **86**:7321–7325.
- Croxford JL (2003) Therapeutic potential of cannabinoids in CNS disease. *CNS Drugs* **17**:179–202.
- Dalrymple MB, Pfeleger KD, and Eidne KA (2008) G protein-coupled receptor dimers: functional consequences, disease states and drug targets. *Pharmacol Ther* **118**:359–371.
- Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, and Portoghesi PS (2005) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. *Proc Natl Acad Sci U S A* **102**:19208–19213.
- Demuth DG and Molleman A (2006) Cannabinoid signalling. *Life Sci* **78**:549–563.
- Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, and Lefkowitz RJ (2008) β -Arrestin-biased agonism at the β_2 -adrenergic receptor. *J Biol Chem* **283**:5669–5676.
- Ellis J, Pediani JD, Canals M, Milasta S, and Milligan G (2006) Orexin-1 receptor-cannabinoid CB₁ receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. *J Biol Chem* **281**:38812–38824.
- Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO, et al. (1998) LY320135, a novel cannabinoid CB₁ receptor antagonist, unmasks coupling of the CB₁ receptor to stimulation of cAMP accumulation. *J Pharmacol Exp Ther* **284**:291–297.
- Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB₁ and CB₂ receptors. *Mol Pharmacol* **48**:443–450.
- Gardner A and Mallet PE (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. *Eur J Pharmacol* **530**:103–106.
- George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of μ - and δ -opioid receptors. Generation of novel functional properties. *J Biol Chem* **275**:26128–26135.
- Georgieva T, Devanathan S, Stropova D, Park CK, Salamon Z, Tollin G, Hruba VJ, Roeske WR, Yamamura HI, and Varga E (2008) Unique agonist-bound cannabinoid CB₁ receptor conformations indicate agonist specificity in signaling. *Eur J Pharmacol* **581**:19–29.
- Gether U (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. *Endocr Rev* **21**:90–113.
- Glass M and Felder CC (1997) Concurrent stimulation of cannabinoid CB₁ and dopamine D₂ receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB₁ receptor. *J Neurosci* **17**:5327–5333.
- Glass M and Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB₁ and CB₂ receptors. *Mol Pharmacol* **56**:1362–1369.
- Hall DA and Strange PG (1997) Evidence that antipsychotic drugs are inverse agonists at D₂ dopamine receptors. *Br J Pharmacol* **121**:731–736.
- Hebert TE, Morello S, Morello JP, Loisel TP, Bichet DG, Barret C, and Bouvier M (1996) A peptide derived from a β_2 -adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. *J Biol Chem* **271**:16384–16392.
- Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, Reynet C, and Wong Kai In P (2007) PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB₁ receptors with hypophagic effects in rats. *Br J Pharmacol* **152**:805–814.
- Hosking RD and Zajicek JP (2008) Therapeutic potential of cannabis in pain medicine. *Br J Anaesth* **101**:59–68.
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* **54**:161–202.
- Hudson BD and Kelly MEM (2008) Interaction Between the CB₁ cannabinoid receptor and the β_2 adrenergic receptor affects CB₁ and β_2 receptor signaling. *18th Annual Symposium of the International Cannabinoid Research Society*; 2008 June 26–29; Aviemore, Scotland, pp 4, International Cannabinoid Research Society, Burlington, VT.
- Jacoby E, Bouhelal R, Gerspacher M, and Seuwen K (2006) The 7 TM G-protein-coupled receptor target family. *Chem Med Chem* **1**:761–782.
- Jampel HD, Lynch MG, Brown RH, Kuhar MJ, and De Souza EB (1987) Beta-adrenergic receptors in human trabecular meshwork. Identification and autoradiographic localization. *Invest Ophthalmol Vis Sci* **28**:772–779.
- Jarrharian A, Watts VJ, and Barker EL (2004) D₂ dopamine receptors modulate G α -subunit coupling of the CB₁ cannabinoid receptor. *J Pharmacol Exp Ther* **308**:880–886.
- Kearn CS, Blake-Palmer K, Daniel E, Mackie K, and Glass M (2005) Concurrent stimulation of cannabinoid CB₁ and dopamine D₂ receptors enhances heterodimer formation: a mechanism for receptor cross-talk? *Mol Pharmacol* **67**:1697–1704.
- Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. *J Biol Chem* **271**:19021–19024.
- Kenakin T (1995a) Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. *Trends Pharmacol Sci* **16**:188–192.
- Kenakin T (1995b) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. *Trends Pharmacol Sci* **16**:232–238.
- Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. *FASEB J* **15**:598–611.
- Lauckner JE, Hille B, and Mackie K (2005) The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB₁ receptor coupling to Gq/11 G proteins. *Proc Natl Acad Sci U S A* **102**:19144–19149.
- Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. *Trends Pharmacol Sci* **28**:382–389.
- Mackie K (2005) Cannabinoid receptor homo- and heterodimerization. *Life Sci* **77**:1667–1673.
- Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, and Galzi JL (2007) A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. *FASEB J* **21**:2124–2134.
- Maneuf YP and Brothie JM (1997) Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. *Br J Pharmacol* **120**:1397–1398.
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* **346**:561–564.
- McIntosh BT, Hudson B, Yegorova S, Jollimore CA, and Kelly ME (2007) Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. *Br J Pharmacol* **152**:1111–1120.
- Mukhopadhyay S and Howlett AC (2005) Chemically distinct ligands promote differential CB₁ cannabinoid receptor-G α protein interactions. *Mol Pharmacol* **67**:2016–2024.
- Pacher P and Haskó G (2008) Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. *Br J Pharmacol* **153**:252–262.
- Panetta R and Greenwood MT (2008) Physiological relevance of GPCR oligomerization and its impact on drug discovery. *Drug Discov Today* **13**:1059–1066.
- Pazos MR, Sagredo O, and Fernández-Ruiz J (2008) The endocannabinoid system in Huntington's disease. *Curr Pharm Des* **14**:2317–2325.
- Pertwee RG (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. *Addict Biol* **13**:147–159.
- Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. *Int J Obes (Lond)* **30** (Suppl 1):S13–S18.
- Pfeleger KD and Eidne KA (2005) Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. *Biochem J* **385**:625–637.
- Piñeyro G (2009) Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling. *Cell Signal* **21**:179–185.
- Piomelli D, Giuffrida A, Calignano A, and Rodríguez de Fonseca F (2000) The endocannabinoid system as a target for therapeutic drugs. *Trends Pharmacol Sci* **21**:218–224.
- Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A,

- McIntosh L, Goodwin G, Walker G, et al. (2005) Allosteric modulation of the cannabinoid CB₁ receptor. *Mol Pharmacol* **68**:1484–1495.
- Rios C, Gomes I, and Devi LA (2006) μ Opioid and CB₁ cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. *Br J Pharmacol* **148**:387–395.
- Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, and Navarro M (2005) The endocannabinoid system: physiology and pharmacology. *Alcohol Alcohol* **40**:2–14.
- Ross RA (2007) Allostery and cannabinoid CB₁ receptors: the shape of things to come. *Trends Pharmacol Sci* **28**:567–572.
- Stamer WD, Golightly SF, Hosohata Y, Ryan EP, Porter AC, Varga E, Noecker RJ, Felder CC, and Yamamura HI (2001) Cannabinoid CB₁ receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. *Eur J Pharmacol* **431**:277–286.
- Terrillon S and Bouvier M (2004) Roles of G-protein-coupled receptor dimerization. *EMBO Rep* **5**:30–34.
- Tsou K, Brown S, Sañudo-Peña MC, Mackie K, and Walker JM (1998) Immunohistochemical distribution of cannabinoid CB₁ receptors in the rat central nervous system. *Neuroscience* **83**:393–411.
- Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christopoulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. *J Biol Chem* **283**:29312–29321.
- Valant C, Sexton PM, and Christopoulos A (2009) Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. *Mol Interv* **9**:125–135.
- Vinod KY and Hungund BL (2006) Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. *Expert Opin Ther Targets* **10**:203–210.
- Wager-Miller J, Westenbroek R, and Mackie K (2002) Dimerization of G protein-coupled receptors: CB₁ cannabinoid receptors as an example. *Chem Phys Lipids* **121**:83–89.
- Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghesi PS, and Whistler JL (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. *Proc Natl Acad Sci U S A* **102**:9050–9055.
- Wanaka A, Kiyama H, Murakami T, Matsumoto M, Kamada T, Malbon CC, and Tohyama M (1989) Immunocytochemical localization of beta-adrenergic receptors in the rat brain. *Brain Res* **485**:125–140.
- Wang H, Guo Y, Wang D, Kingsley PJ, Marnett LJ, Das SK, DuBois RN, and Dey SK (2004) Aberrant cannabinoid signaling impairs oviductal transport of embryos. *Nat Med* **10**:1074–1080.
- Xie Z, Bhushan RG, Daniels DJ, and Portoghesi PS (2005) Interaction of bivalent ligand KDN21 with heterodimeric δ - κ opioid receptors in human embryonic kidney 293 cells. *Mol Pharmacol* **68**:1079–1086.
- Yan F, Mosier PD, Westkaemper RB, and Roth BL (2008) G α -subunits differentially alter the conformation and agonist affinity of κ -opioid receptors. *Biochemistry* **47**:1567–1578.

Address correspondence to: Dr. Melanie E. M. Kelly, Department of Pharmacology, Dalhousie University, 5850 College St., Halifax, Nova Scotia, Canada, B3H 1X5. E-mail: melanie.kelly@dal.ca
